Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.33 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30670701 | 1.00 | TRPV4 (0.35) | TRPV4KHKCYP11B2CYP11B1SLC1A5 | |
| SCHEMBL16098127 | 0.84 | TRPV4 (0.38) | TRPV4KHKCYP11B2CYP11B1SLC1A5 | |
| SCHEMBL30107963 | 0.78 | TRPV4 (0.38) | TRPV4KHKCYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL16581287 | 0.78 | GPR35 (0.41) | TRPV4CYP11B2CYP11B1GPR35MAOA | |
| SCHEMBL29560065 | 0.78 | TRPV4 (0.39) | TRPV4KHKCYP11B2CYP11B1GPR35 | |
| SCHEMBL7922013 | 0.78 | TRPV4 (0.38) | TRPV4KHKCYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL9693924 | 0.78 | GPR35 (0.41) | TRPV4KHKCYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL504867 | 0.78 | TRPV4 (0.39) | TRPV4KHKCYP11B2CYP11B1GPR35 | |
| SCHEMBL4521310 | 0.77 | TRPV4 (0.36) | TRPV4SLC1A5ALDH1A1NMT1GPR35 | |
| SCHEMBL16122643 | 0.77 | GRM5 (0.42) | TRPV4KHKCYP11B2ALDH1A1VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250252-A1 | PIPERIDINYLBENZONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-07 | — | — | US | disclosed |
| EP-4558492-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025056068-A1 | BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海济煜医药科技有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119654315-A | 3- (6-Pyridin-3-yl) -2- [4- (4-methyl-4H-1, 2, 4-triazol-3-yl) piperidin-1-yl ] benzonitrile derivatives and similar compounds as QPCTL and QPCT inhibitors for the treatment of cancer | 858治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| EP-2655378-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | AstraZeneca AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| CN-103380133-A | Compounds and their use as BACE inhibitors | ASTRAZENECA AB | 2013-10-30 | — | — | CN | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250252-A1 | PIPERIDINYLBENZONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | TRPV4 4683/4885KHK 2563/4885CYP11B2 3408/4885 |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | TRPV4 4147/4885KHK 3744/4885CYP11B2 536/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | TRPV4 4147/4885KHK 3744/4885CYP11B2 536/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | TRPV4 2148/4885KHK 3169/4885CYP11B2 159/4885 |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | ACAT1, ACAT2, LCAT | TRPV4 4778/4885KHK 2361/4885CYP11B2 725/4885 |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, SHBG, NR5A1 | TRPV4 1249/4885KHK 1739/4885CYP11B2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.